Gilla Kaplan's Insider Trades & SAST Disclosures
Gilla Kaplan's most recent trade in Avalo Therapeutics Inc was a trade of 3,167 Common Stock done . Disclosure was reported to the exchange on March 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gilla Kaplan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 61,392 | 0 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 13 Jun 2024 | 61,392 | 89,623 | - | 0.6 | 37,449 | Common Stock |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 18,600 | 18,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,080 | 3,080 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 44,115 | 44,115 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 30,359 | 30,359 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 9,541 | 9,541 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 6,353 | 6,353 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges